List view / Grid view
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…
According to a new report, artificial intelligence (AI) is vital for the rapid identification of drugs that can be repurposed to combat COVID-19.
Researchers found breast cancer cells reprogrammed natural killer T cells, altering gene expression and receptor expression so they help cancerous metastases spread.
The vitamin K-based drug has a unique structure which researchers believe makes it effective in controlling even medication-resistant seizures.
To overcome the issues of current analgesics, researchers reveal a new class of non-narcotic pipeline drugs based on acetaminophen.
Two molecules combined into a new substance to treat type 2 diabetes lowered blood sugar in shrew models without causing nausea, vomiting and weight loss.
Dr Sarah Doyle and Dr Ema Ozaki outline their research into SARM1 and why it presents an attractive target for treating retinal degeneration.
Researchers recently conducted a genome-wide association study (GWAS) to identify factors that increase susceptibility to the incurable lung condition idiopathic pulmonary fibrosis (IPF). Here, Dr Richard Allen shares some of the study’s key findings.
Sheraz Gul explores current research developments to help treat and tackle the spread of COVID-19.
The heterogeneous pathogenesis of metabolic fatty liver diseases presents researchers with numerous challenges when trying to develop a treatment. This article explores the spectrum of these diseases and presents a novel in vitro platform for screening drug candidates.
Dr Bernard Fox from Providence Cancer Institute explains how OncoSec’s CORVax12 vaccine works to potentially combat COVID-19.
Researchers in Boston have repurposed their lab into a centre to test samples for COVID-19, releasing a blueprint of how to do so for other labs in the US.
With the global ageing population at risk of death from influenza, what is pharma doing to develop more effective vaccines to combat the virus?
Drug Target Review rounds up the latest announcements regarding funding for research into COVID-19 treatments and vaccines.
Grifols will leverage their resources to develop and test convalescent plasma-derived COVID-19 therapeutics in partnership with the FDA and BARDA.
